Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation
- PMID: 19969084
- DOI: 10.1016/j.nbd.2009.11.018
Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation
Abstract
Inflammation, and in particular microglia activation, is regarded as a constant component of brain pathology in Parkinson's disease (PD). Microglial activation has been found in the substantia nigra (SN), one of the main brain regions affected in PD, for many years after the initiation of the disease. Although many studies point towards a deleterious role of inflammation on PD, the functional role of many of its main components has not been clarified yet. For example, tumor necrosis factor-alpha (TNF-alpha), a key pro-inflammatory cytokine, has been shown to exert toxic or no effects on the viability of dopaminergic neurons. No study has evaluated the effects of the long-lasting TNF-alpha expression in the SN, an experimental set-up most probably resembling the clinical situation. The aim of this study was to investigate the effects of the chronic expression of TNF-alpha in the adult SN at different time points. Adenoviral expression of low TNF-alpha levels (17-19 pg/mg) lasted for 14 days in the SN and did not induce interleukin-1beta (IL-1beta) expression. Long-lasting TNF-alpha expression caused dopaminergic cell death from day 14, increasing at 21 and 28 days compared with control animals injected with adenovectors expressing beta-galactosidase. TNF-alpha overexpression elicited irreversible, unilateral akinesia starting at 14 days, but not earlier. These effects were accompanied by microglial activation to stage 4 and/or monocyte/macrophage recruitment from the periphery from day 7 post adenovector inoculations. Thus, we conclude that extended duration of the expression of TNF-alpha is necessary and sufficient for a univocal toxic effect of TNF-alpha on dopaminergic neurons and motor disabilities. This study provides an animal model to study early events that lead to TNF-alpha-mediated neuronal demise in the SN. In addition, the cellular components of the inflammation elicited by TNF-alpha and the lack of IL-1beta expression support the growing idea of a distinct cytokine network in the brain.
2009 Elsevier Inc. All rights reserved.
Similar articles
-
Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra.Neurobiol Dis. 2006 Oct;24(1):183-93. doi: 10.1016/j.nbd.2006.06.013. Epub 2006 Aug 9. Neurobiol Dis. 2006. PMID: 16901708
-
Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice.Exp Neurol. 2011 Feb;227(2):237-51. doi: 10.1016/j.expneurol.2010.11.010. Epub 2010 Nov 17. Exp Neurol. 2011. PMID: 21093436
-
Nigral neurodegeneration triggered by striatal AdIL-1 administration can be exacerbated by systemic IL-1 expression.J Neuroimmunol. 2010 May;222(1-2):29-39. doi: 10.1016/j.jneuroim.2010.02.018. Epub 2010 Mar 29. J Neuroimmunol. 2010. PMID: 20350768
-
Glial reactions in Parkinson's disease.Mov Disord. 2008 Mar 15;23(4):474-83. doi: 10.1002/mds.21751. Mov Disord. 2008. PMID: 18044695 Review.
-
Neuroimmunomodulation in the pathogenesis of Alzheimer's disease.Neuroimmunomodulation. 2010;17(3):202-4. doi: 10.1159/000258724. Epub 2010 Feb 4. Neuroimmunomodulation. 2010. PMID: 20134203 Review.
Cited by
-
The degenerating substantia nigra as a susceptible region for gene transfer-mediated inflammation.Parkinsons Dis. 2011;2011:931572. doi: 10.4061/2011/931572. Epub 2011 May 29. Parkinsons Dis. 2011. PMID: 21687774 Free PMC article.
-
Understanding the Pre-Clinical Stages of Parkinson's Disease: Where Are We in Clinical and Research Settings?Int J Mol Sci. 2025 Jul 17;26(14):6881. doi: 10.3390/ijms26146881. Int J Mol Sci. 2025. PMID: 40725128 Free PMC article. Review.
-
Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson's Disease?Front Cell Neurosci. 2013 Apr 29;7:53. doi: 10.3389/fncel.2013.00053. eCollection 2013. Front Cell Neurosci. 2013. PMID: 23641196 Free PMC article.
-
Neuroprotective Effect of Echinacoside in Subacute Mouse Model of Parkinson's Disease.Biomed Res Int. 2019 Jan 30;2019:4379639. doi: 10.1155/2019/4379639. eCollection 2019. Biomed Res Int. 2019. PMID: 30834264 Free PMC article.
-
Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases.Mediators Inflamm. 2014;2014:465694. doi: 10.1155/2014/465694. Epub 2014 Jul 16. Mediators Inflamm. 2014. PMID: 25132733 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical